Lipoprotein(a) and Immunity

Афанасьева, О. И.; Arefieva, T. I.; Ezhov, Marat; Pokrovsky, S.

doi:10.1007/978-3-031-24575-6_16

Cited by 3 publications

(4 citation statements)

References 82 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The potential role of Lp(a) as an activator of immune system cells is actively debated [ 47 ]. In particular, monocytes isolated from the blood of individuals with elevated Lp(a) levels showed increased secretion of proinflammatory cytokines and decreased secretion of anti-inflammatory cytokines [ 48 ].…”

Section: Discussionmentioning

confidence: 99%

Lipoprotein(a) and Low-Molecular-Weight Apo(a) Phenotype as Determinants of New Cardiovascular Events in Patients with Premature Coronary Heart Disease

Afanasieva,

Tyurina,

Ezhov

et al. 2023

Diseases

Self Cite

View full text Add to dashboard Cite

Background. Lipoprotein(a) (Lp(a)) is a genetic risk factor of atherosclerotic cardiovascular diseases (ASCVDs). Proprotein convertase subtilisin/kexin type 9 (PCSK9) is related to vascular inflammation and detected in atherosclerotic plaques. A temporary increase in the circulating concentration of PCSK9 and Lp(a) was shown in patients with myocardial infarction (MI). The aim of this study was to evaluate the role of the apo(a) phenotype and the Lp(a) concentration as well as its complex with PCSK9 in the development of cardiac events and MI in patients with a premature manifestation of coronary heart disease (CHD). Methods. In a prospective study with retrospective data collection, we included 116 patients with premature CHD who were followed for a median of 14 years. The medical history and information on cardiovascular events after an initial exam as well as data on the levels of lipids, Lp(a), PCSK9, PCSK9-Lp(a) complex, and apo(a) phenotype were obtained. Results. The patients were divided into two groups depending on the presence of a low- (LMW, n = 52) or high-molecular weight (HMW, n = 64) apo(a) phenotype. LMW apo(a) phenotype (odds ratio 2.3 (1.1 to 4.8), p = 0.03), but not elevated Lp(a) (1.9 (0.8–4.6), p = 0.13), was an independent predictor for the development of MI after adjustment for sex, age of CHD debut, initial lipids levels, and lipid-lowering treatment. The apo(a) phenotype also determined the relationship between Lp(a) and PCSK9 concentrations. The level of the PCSK9-Lp(a) complex was higher in LMW apo(a) patients. Conclusion. The LMW apo(a) phenotype is a risk factor for non-fatal MI in a long-term prospective follow-up of patients with premature CHD, and this link could be mediated via PCSK9.

show abstract

Section: Discussionmentioning

confidence: 99%

Lipoprotein(a) and Low-Molecular-Weight Apo(a) Phenotype as Determinants of New Cardiovascular Events in Patients with Premature Coronary Heart Disease

Afanasieva,

Tyurina,

Ezhov

et al. 2023

Diseases

Self Cite

View full text Add to dashboard Cite

show abstract

“…Повышенный уровень Лп(а) в крови является доказанным и независимым ФР ранней манифестации атеросклероза различных сосудистых бассейнов и ассоциированных с ним сердечнососудистых осложнений в молодом и среднем возрасте [6]. Лп(а) локализуется в богатых макрофагами участках атеросклеротических бляшек человека [7]. Предполагается, что он может активировать клетки неспецифического иммунитета [7], однако до конца механизм его атерогенного действия пока не изучен.…”

Section: изучение активации нейтрофильных гранулоцитов в присутствии ...unclassified

“…Лп(а) локализуется в богатых макрофагами участках атеросклеротических бляшек человека [7]. Предполагается, что он может активировать клетки неспецифического иммунитета [7], однако до конца механизм его атерогенного действия пока не изучен.…”

Section: изучение активации нейтрофильных гранулоцитов в присутствии ...unclassified

“…Воспалительный потенциал Лп(а) может быть опосредован прямым действием входящих в его состав окисленных фосфолипидов на рецепторы клеток врожденного иммунитета, а также его способностью образовывать комплексы с провоспалительными молекулами [7]. Выявление механизмов реализации провоспалительной активности Лп(а) требует дальнейших исследований.…”

Section: заключениеunclassified

See 1 more Smart Citation

Number of blood neutrophil granulocytes is associated with diffuse coronary involvement in patients with increased lipoprotein (a)

Filatova,

Larina,

Afanasieva

et al. 2023

Russ J Cardiol

Self Cite

View full text Add to dashboard Cite

Aim. To assess the level of lipoprotein (a) (Lp(a)) and other lipid profile parameters, the composition of blood leukocytes in patients with focal and diffuse coronary atherosclerosis who underwent coronary artery bypass surgery (CABG), as well as to study the effect of Lp(a) on the activation of leukocytes in vitro.Material and methods. The study included 120 male patients (mean age, 67±5 years) with multivessel coronary artery disease after elective CABG surgery. According to the type of coronary artery involvement, patients were divided into groups of diffuse (n=77) and focal (n=43) atherosclerosis. In peripheral blood samples, the content of the main fractions of lipoproteins, including Lp(a), was determined. Activation of neutrophil granulocytes upon addition of Lp(a) was assessed in whole blood and in primary cell culture.Results. In patients with diffuse coronary stenosis, there was a tendency to higher Lp(a) levels; no changes in other lipid profile parameters were detected. In this group of patients, an increase in the absolute leukocyte count was noted due to neutrophilic granulocytes. An absolute neutrophil count >2,9 million/mL was associated with diffuse disease (AUC, 0,69 (95% confidence interval (CI) 0,600,77), p=0,0002, sensitivity 85%, specificity 42%). In patients with Lp(a) ³30 mg/dL, the diagnostic value of a neutrophil count >2,9 million/mL for diffuse stenosis was higher (AUC, 0,74 (95% CI 0,60-0,86), p= 0,005, sensitivity 90%, specificity 48%). According to logistic regression analysis with the introduction of neutrophils and conventional risk factors (age, body mass index, hypertension and smoking) into the model, only the number of neutrophils above the threshold level remained an independent factor in diffuse coronary stenosis. Lp(a) can induce neutrophil activation, detected by increased CD66b overexpression in whole blood, as well as the formation of neutrophil extracellular traps in primary cell culture.Conclusion. Neutrophil granulocytes can participate in the formation of diffuse atherosclerotic coronary lesions. One of the neutrophil activators may be Lp(a). The combination of high neutrophil count and Lp(a) level in the blood increases the risk of diffuse coronary atherosclerosis.

show abstract

Lipoprotein(a) and triglyceride-rich lipoproteins — association with recurrent nonfatal myocardial infarction in patients with early manifestation of coronary artery disease

Afanasieva,

Arefieva,

Tyurina

et al. 2024

Kardio. vestn.

View full text Add to dashboard Cite

Lipoprotein(a) and Immunity

Cited by 3 publications

References 82 publications

Lipoprotein(a) and Low-Molecular-Weight Apo(a) Phenotype as Determinants of New Cardiovascular Events in Patients with Premature Coronary Heart Disease

Lipoprotein(a) and Low-Molecular-Weight Apo(a) Phenotype as Determinants of New Cardiovascular Events in Patients with Premature Coronary Heart Disease

Number of blood neutrophil granulocytes is associated with diffuse coronary involvement in patients with increased lipoprotein (a)

Lipoprotein(a) and triglyceride-rich lipoproteins — association with recurrent nonfatal myocardial infarction in patients with early manifestation of coronary artery disease

Contact Info

Product

Resources

About